/

Società

Ce

Non verificato

Cellares

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMercato del lavoroSalute

30 comunicati stampa

Guarda tutti i comunicati

21/07/2026

Cellares and Papillon Therapeutics Partner to Automate Manufacturing of PPL-001 for Patients With Friedreich’s Ataxia

Fonte

Emittente

1.00

0

13/07/2026

Cellares and Sonoma Biotherapeutics Collaborate to Automate Manufacturing of SBT-77-7101 Engineered Treg Cell Therapy on the Cell Shuttle® Platform

Fonte

Emittente

1.00

0

30/06/2026

Cellares Accepted to FDA's Inaugural Manufacturing PreCheck Cohort, the Only Cell Therapy Platform Among Seven Companies Nationwide

Fonte

Emittente

1.00

0

15/06/2026

Cellares Grows Series D to $327 Million with $50 Million Prime Radiant Partners Investment

Fonte

Emittente

1.00

0

10/06/2026

Cellares Joins New American Industrial Alliance, Advancing U.S. Biopharmaceutical Manufacturing Independence

Fonte

Emittente

1.00

0

09/06/2026

Cathie Wood's ARK Invest Joins Cellares' $277 Million Series D

Fonte

Emittente

1.00

0

03/06/2026

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

Fonte

Emittente

1.00

0

11/05/2026

Cellares and ProTgen Partner to Automate Manufacturing for ProT-096, a Novel Progenitor T Cell Therapy Designed to Restore Immune Competence

Fonte

Emittente

1.00

0

28/04/2026

Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel

Fonte

Emittente

1.00

0

14/04/2026

First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0